Trials / Completed
CompletedNCT00330395
Open, Pharmacokinetic Study of Caspofungin in Neonates and Infants (0991-058)
A Multicenter, Sequential-Panel, Open-Label, Noncomparative Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Caspofungin Acetate in Neonates and Infants Less Than 3 Months of Age.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 3 Months
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the amount of caspofungin found in the blood of neonate and infants \<3 months of age following treatment with caspofungin at 25 mg/m2. Another purpose is to test the safety of caspofungin in treating neonates and infants with Candida infections (a certain type of fungal infection).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | caspofungin acetate | Duration of Treatment 28 Days |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2006-10-01
- Completion
- 2006-10-01
- First posted
- 2006-05-26
- Last updated
- 2017-02-23
Source: ClinicalTrials.gov record NCT00330395. Inclusion in this directory is not an endorsement.